All News
Filter News
Found 192 articles
-
Merck Announces Third-Quarter 2021 Financial Results
10/28/2021
Merck, known as MSD outside the United States and Canada, announced financial results for the third quarter of 2021.
-
The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries
10/27/2021
The Medicines Patent Pool and Merck, known as MSD outside the United States and Canada, announced the signing of a voluntary licensing agreement to facilitate affordable global access for molnupiravir, an investigational oral COVID-19 antiviral medicine for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization.
-
Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults
10/25/2021
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the European Medicines Agency has initiated a rolling review for molnupiravir, an investigational oral antiviral medicine, for the treatment of COVID-19 in adults.
-
COVID News: Pregnant Women Urged to Get Vaccine, UK Health Experts Push for New Restrictions and ...
10/20/2021
The CDC has warned that COVID-19 during pregnancy can result in preterm birth and other negative outcomes, including stillbirths. -
Ridgeback Biotherapeutics Responds to 13th Ebola Outbreak in Democratic Republic of Congo
10/20/2021
Ridgeback Biotherapeutics, a biotechnology company experienced in antiviral drug development including medicines to treat SARS-Cov-2 and Ebola, announces deployment of the Ridgeback Ebola Rapid Response team to the Democratic Republic of the Congo.
-
Bill & Melinda Gates Foundation Commits up to $120 Million to Accelerate Access to COVID-19 Drug for Lower-Income Countries, Calls on Other Donors to Mobilize Resources
10/20/2021
The Bill & Melinda Gates Foundation announced a commitment of up to $120 million to accelerate access to the investigational antiviral drug molnupiravir for lower-income countries as part of its COVID-19 response effort.
-
FDA to Hold Advisory Committee Meeting to Discuss Merck and Ridgeback's EUA Application for COVID-19 Oral Treatment
10/14/2021
Today, the U.S. Food and Drug Administration is announcing an upcoming meeting of its Antimicrobial Drugs Advisory Committee (AMDAC) to discuss Merck and Ridgeback's request for an emergency use authorization (EUA) for molnupiravir, an investigational antiviral drug to treat COVID-19.
-
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
10/13/2021
NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021 with the Securities and Exchange Commission on Tuesday, October 12, 2021.
-
If authorized, it could be available in the U.S. before the end of the year. It is also working to submit applications to other regulators worldwide.
-
Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
10/11/2021
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that Merck has submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization.
-
Here’s a look at mRNA vaccines and their effectiveness and more COVID-19 news.
-
Newly appointed CEO Rob Davis must find a way to balance Merck’s portfolio before investors get (even more) antsy. And he is looking to be aggressive.
-
There is a noted discrepancy between the price the U.S. government has agreed to pay Merck for the drug and the actual manufacturing costs.
-
Johnson & Johnson is expected to ask the U.S. Food and Drug Administration to authorize a booster for its one-shot COVID-19 vaccine this week.
-
The Phase III trial on a potential treatment for mild-to-moderate COVID-19 symptoms by Merck and Ridgeback Biotherapeutics showed promise in preventing hospitalizations and death.
-
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50% Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
10/1/2021
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19.
-
Garuda Therapeutics Launches with $72 Million Series A Financing
9/23/2021
Garuda Therapeutics launched today with an oversubscribed $72 million Series A financing led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management
-
Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19
9/22/2021
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the execution of an in-license agreement with the University Medical Center Goettingen, Germany, covering the combination of DHODH inhibitors and nucleoside analogues to treat viral infections.
-
Data coming in about the COVID-19 pandemic shows some promising overall trends, with other more disturbing ones, particularly in breakthrough infections of the fully vaccinated.
-
The study of Molnupiravir will assess 1,300 adult participants 18 and over who cohabitate with someone who has tested positive for the coronavirus and is symptomatic.